S
Saulnier Mark G
Researcher at Bristol-Myers Squibb
Publications - 97
Citations - 3319
Saulnier Mark G is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Indole test & Ring (chemistry). The author has an hindex of 29, co-authored 97 publications receiving 3260 citations. Previous affiliations of Saulnier Mark G include Stanford University & Dartmouth College.
Papers
More filters
Patent
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
TL;DR: In this paper, a method for the delivery of cytotoxic drugs to tumor cells by the administration of a tumor-specific antibody-enzyme conjugate that binds to the tumor cells, and the additional administration of an additional prodrug that is converted at the tumor site, in the presence of the antibody-bound enzyme, to an active cytotoxicity drug.
Journal ArticleDOI
Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate.
Peter D. Senter,Saulnier Mark G,Schreiber George J,David L. Hirschberg,Joseph P. Brown,Ingegerd Hellström,Karl Erik Hellström +6 more
TL;DR: Two anti-tumor monoclonal antibodies, L6 (anticarcinoma) and 1F5 (anti-B lymphoma), were covalently linked to alkaline phosphatase (AP), forming conjugates that could bind to the surface of antigen-positive tumor cells, capable of converting a relatively noncytotoxic prodrug into etoposide--a drug with significant antitumor activity.
Journal ArticleDOI
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor
Joan M. Carboni,Adrian V. Lee,Darryl L. Hadsell,Bruce Rowley,Francis Y.F. Lee,David Bol,Amy Camuso,Marco M. Gottardis,Ann Greer,Ching Ping Ho,Warren Hurlburt,Aixin Li,Saulnier Mark G,Upender Velaparthi,Cindy Wang,Mei-Li Wen,Richard A. Westhouse,Mark D. Wittman,Kurt Zimmermann,Brent A. Rupnow,Tai W. Wong +20 more
TL;DR: A novel animal model that involves transgenic expression of a fusion receptor that is constitutively activated by homodimerization is described that should provide new opportunities for further understanding how aberrant IGF-IR signaling leads to tumorigenesis and for optimizing novel antagonists of the receptor kinase.
Journal ArticleDOI
In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
Paul Haluska,Joan M. Carboni,David A. Loegering,Francis Y. Lee,Mark D. Wittman,Saulnier Mark G,David B. Frennesson,Kimberly R. Kalli,Cheryl A. Conover,Ricardo M. Attar,Scott H. Kaufmann,Marco M. Gottardis,Charles Erlichman +12 more
TL;DR: BMS-554417 is a member of a novel class of IGF-IR/insulin receptor inhibitors that have potential clinical applications because of their antiproliferative and proapoptotic activity in vitro and in vivo.
Journal ArticleDOI
Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.
Mark D. Wittman,Joan M. Carboni,Ricardo M. Attar,Balu Balasubramanian,Praveen Balimane,Patrick J. Brassil,Francis Beaulieu,Chiehying Chang,Wendy Clarke,Janet Dell,Jeffrey Eummer,David B. Frennesson,Marco M. Gottardis,Ann Greer,Steven Hansel,Warren Hurlburt,Bruce L. Jacobson,Subramaniam Krishnananthan,Francis Y. Lee,Aixin Li,Tai-An Lin,Peiying Liu,Carl Ouellet,Xiaopeng Sang,Saulnier Mark G,Stoffan Karen M,Yax Sun,Upender Velaparthi,Henry Wong,Zheng Yang,Kurt Zimmermann,Zoeckler Mary Edson,Dolatrai M. Vyas +32 more
TL;DR: Compound 3 (BMS-536924), a novel small-molecule inhibitor of the insulin-like growth factor receptor kinase with equal potency against the insulin receptor is described.